GT Biopharma (GTBP) Fundamental Analysis: Revenue, Earnings & Valuation

8.75 / 10

Outperform

Fundamentals score 8.75, rated Outperform. Revenue growth exceeds 130% YoY, inventory turnover is strong, and interest coverage is high. However, long‑term debt to working capital and current liabilities ratios are weak, dragging the debt profile.

Analysis Checks(7/10)

Revenue-MV

Value-0.11

Score3/3

Weight82.64%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value134.00

Score2/3

Weight1.13%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-9.42%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value100.00

Score0/3

Weight-34.92%

1M Return-4.96%

PB-ROE

Value-0.83

Score2/3

Weight77.08%

1M Return7.29%

Long-term debt to working capital ratio (%)

Value6.39

Score0/3

Weight-35.90%

1M Return-4.75%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-9.58%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value177.16

Score2/3

Weight0.46%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-9.05%

1M Return-1.13%

Asset-MV

Value-0.55

Score0/3

Weight37.56%

1M Return4.00%

Is GTBP undervalued or overvalued?

GTBP scores 8.75/10 on fundamentals and holds a Discounted valuation at present. Backed by its -1673.50% ROE, 0.00% net margin, -0.37 P/E ratio, 2.23 P/B ratio, and 3.75% earnings growth, these metrics solidify its Outperform investment rating.